News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEvents
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

MaryBeth Freeman, MPH

Advertisement

Articles by MaryBeth Freeman, MPH

Prostate Cancer Diagnoses Decrease With Lenient Screening Recommendations

ByMaryBeth Freeman, MPH
May 8th 2019

After the USPSTF advised against prostate cancer screening for all men, there was a decrease in the incidence of the disease.

Advertisement

Latest Updated Articles

  • Prostate Cancer Diagnoses Decrease With Lenient Screening Recommendations
    Prostate Cancer Diagnoses Decrease With Lenient Screening Recommendations

    Published: May 8th 2019 | Updated:



Advertisement
Advertisement

Trending on Oncology Nursing News

1

FDA Greenlights Niraparib/Abiraterone Acetate With Prednisone in mHSPC

2

Oral Azacitidine Yields Similar PK to Subcutaneous Azacitidine in MDS/CMML

3

Pembrolizumab Plus RT Ups T-Cell Infiltration in Early Breast Cancer

4

Teclistamab/Daratumumab Increases OS, PFS in R/R Multiple Myeloma

5

Progression Occurs Early in R/R LBCL Treated With Epcoritamab, Glofitamab

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us